SSC and PAH
SSC and PAH
What is PAH?
A subtype of pulmonary hypertension (PH)
Pulmonary arterial hypertension (PAH) is a rare, progressive disease characterised by elevated pulmonary arterial pressure and vascular resistance that eventually leads to right ventricular failure and death[1]
Early identification and intervention are key to changing the course of the disease[2]
PAH is a severe and often fatal complication of CTD:[3]
- It is most commonly seen in SSc, accounting for 75% of CTD-PAH cases[4]
- Approximately 1 in 10 patients with SSc are estimated to have PAH[5]
PAH is a leading cause of death in patients with SSc, accounting for >50% of deaths in SSc-PAH patients[6]
Adapted from Badesch et al. 2010[7]
Component not published? componentType is undefined.
Contact
Want to know more? Contact our medical team!
MATHIJS KRUK
Medical Scientific Liaison Pulmonary
Hypertension NL
+31 6 1238 17 11
[email protected]
ROB JANSSEN, PHD
Medical Advisor Pulmonary
Hypertension NL
+31 6 53 72 73 03
[email protected]
Contacteer ons
Hebt u een vraag voor ons of niet
Ontdek onze producten
Ontdek hier het Johnson & Johnson portfolio en de bijbehorende SmPC's.
Bekijk 3D-ziektebeelden
Ontdek interactieve 3D-animaties van de menselijke anatomie en verschillende ziektebeelden.
Abbreviations
ALT, alanine aminotransferase; AST, aspartate aminotransferase;CHD, congenital heart disease; CI, confidence interval; CTD, connective tissue disease; ERA, endothelin receptor antagonist; ERS, European Respiratory Society; ESC, European Society of Cardiology; HIV, human immunodeficiency virus; HPAH, heritable pulmonary arterial hypertension; HR, hazard ratio; IPAH, idiopathic pulmonary arterial hypertension; LFT, liver function test; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; PoPH, portopulmonary hypertension; RHC, right heart catheterisation; SSc, systemic sclerosis; TRV, tricuspid regurgitation velocity; ULN, upper limit of normal; 6MWD, six-minute walk distance
CP-192318 - November 2020
